Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Terpos
Evangelos
E
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D001897:Boronic Acids / Q000008:administration & dosage* / Q000494:pharmacology; D000069286:Bortezomib; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D020551:Pulse Therapy, Drug; D011719:Pyrazines / Q000008:administration & dosage* / Q000494:pharmacology
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib